激素联合氨己烯酸治疗婴儿痉挛症的安全性与有效性:ICISS随机多中心开放标签试验
ICISS试验纳入377例婴儿痉挛症患儿,随机分为激素联合氨己烯酸组(186例)和单用激素组(191例)。联合治疗显著更有效,严重不良反应两组相近。
要点
- 激素联合氨己烯酸组痉挛停止率72%,显著高于单用激素组的57%。
- 联合组与单用组严重不良反应需住院分别为17例和16例,无治疗相关死亡。
- 联合治疗可提高短期痉挛控制率,但长期疗效需18个月随访确认。
核心结论
- 激素联合氨己烯酸在停止婴儿痉挛发作方面显著优于单用激素治疗。
研究设计与样本
- 多中心、开放标签、随机对照试验,纳入102家医院(澳大利亚3家、德国11家、新西兰2家、瑞士3家、英国83家)的婴儿痉挛症患儿。
- 共筛查766例,随机分配377例至激素联合氨己烯酸组(186例)或单用激素组(191例),按1:1比例,区组随机分层因素为激素类型和发育障碍风险。
- 主要终点为第14至42天(含)父母/照护者日记记录的痉挛停止,采用意向性治疗分析。
主要发现
- 严重不良反应需住院:联合组17例,单用组16例;最常见严重不良反应为感染(联合组4例,单用组5例)。
- 无治疗相关死亡。
关键数值与推荐
- 氨己烯酸剂量:100 mg/kg/天(联合组)。
- 主要终点定义:第14至42天(含)无目击痉挛发作。
临床怎么用
- 对于婴儿痉挛症患儿,可考虑激素联合氨己烯酸作为初始治疗方案以提高短期痉挛控制率。
- 治疗期间需监测感染等严重不良反应,两组严重不良反应发生率相近。
局限性
- 开放标签设计,父母和临床医生未设盲,但电临床结局评估者设盲。
- 4周痉挛停止期所显示的效应可能持续,但需18个月随访确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infantile spasms constitutes a severe infantile epilepsy syndrome that is difficult to treat and has a high morbidity. Hormonal therapies or vigabatrin are the most commonly used treatments. We aimed to assess whether combining the treatments would be more effective than hormonal therapy alone. METHODS: In this multicentre, open-label randomised trial, 102 hospitals (Australia [three], Germany [11], New Zealand [two], Switzerland [three], and the UK [83]) enrolled infants who had a clinical diagnosis of infantile spasms and a hypsarrhythmic (or similar) EEG no more than 7 days before enrolment. Participants were randomly assigned (1:1) by a secure website to receive hormonal therapy with vigabatrin or hormonal therapy alone. If parents consented, there was an additional randomisation (1:1) of type of hormonal therapy used (prednisolone or tetracosactide depot). Block randomisation was stratified for hormonal treatment and risk of developmental impairment. Parents and clinicians were not masked to therapy, but investigators assessing electro-clinical outcome were masked to treatment allocation. Minimum doses were prednisolone 10 mg four times a day or intramuscular tetracosactide depot 0·5 mg (40 IU) on alternate days with or without vigabatrin 100 mg/kg per day. The primary outcome was cessation of spasms, which was defined as no witnessed spasms on and between day 14 and day 42 from trial entry, as recorded by parents and carers in a seizure diary. Analysis was by intention to treat. The trial is registered with The International Standard Randomised Controlled Trial Number (ISRCTN), number 54363174, and the European Union Drug Regulating Authorities Clinical Trials (EUDRACT), number 2006-000788-27. FINDINGS: Between March 7, 2007, and May 22, 2014, 766 infants were screened and, of those, 377 were randomly assigned to hormonal therapy with vigabatrin (186) or hormonal therapy alone (191). All 377 infants were assessed for the primary outcome. Between days 14 and 42 inclusive no spasms were witnessed in 133 (72%) of 186 patients on hormonal therapy with vigabatrin compared with 108 (57%) of 191 patients on hormonal therapy alone (difference 15·0%, 95% CI 5·1-24·9, p=0·002). Serious adverse reactions necessitating hospitalisation occurred in 33 infants (16 on hormonal therapy alone and 17 on hormonal therapy with vigabatrin). The most common serious adverse reaction was infection occurring in five infants on hormonal therapy alone and four on hormonal therapy with vigabatrin. There were no deaths attributable to treatment. INTERPRETATION: Hormonal therapy with vigabatrin is significantly more effective at stopping infantile spasms than hormonal therapy alone. The 4 week period of spasm cessation required to achieve a primary clinical response to treatment suggests that the effect seen might be sustained, but this needs to be confirmed at the 18 month follow-up. FUNDING: The Castang Foundation, Bath Unit for Research in Paediatrics, National Institute of Health Research, the Royal United Hospitals Bath NHS Foundation Trust, the BRONNER-BENDUNG Stifung/Gernsbach, and University Children's Hospital Zurich.
引用
- O'Callaghan FJ, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2016. PMID: 27838190. doi:10.1016/S1474-4422(16)30294-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。